期刊文献+

吉非替尼治疗化疗失败的晚期非小细胞肺癌疗效分析 被引量:1

Treatment with gefitinib in advanced non-small-cell lung cancer patients who failed in previous chemotherapy
下载PDF
导出
摘要 目的探讨吉非替尼单药治疗化疗失败的晚期非小细胞肺癌的疗效及不良反应。方法对45例IIIB~IV期经化疗失败的晚期非小细胞肺癌用吉非替尼每次250 mg/d口服。第一次用药后4周评价疗效,以后每8周1次或出现新的症状及原有症状加重时随时评价。结果45例均可评价疗效,完全缓解(CR)1例,部分缓解(PR)15例,客观缓解率(CR+PR)为35.6%;疾病控制率(CR+PR+SD)为68.9%。不良反应:30例有皮肤改变表现(脱屑、座疮),15例有轻度腹泻。结论吉非替尼对化疗失败晚期非小细胞肺癌具有一定疗效,不良反映轻微。 Objective To evaluate the efficacy and adverse effects of single - drug Iressa in treatment of non - small - cell lung cancer (NSCLC) patients who failed in previous chemotherapy. Methods Forty - five patients with stage ⅢB~Ⅳ NSCLC who had failed chemotherapy received 250 mg oral dises of gefitinib. Four weeks after the start of gefitinib the effect was assessed, then once every 8 weeks or if the symptom progressed,the evaluation was repeated. Results All 45 patients were evaluable, overall response rate was 40% , and disease control rate (DCR) was 73.3% which included 2 complete response ( CR ), 16partial response ( PR ), 15 stable disease. The most common Adverse effects were rash and diarrhea with 66.7% and 33.3% ,respectively. Conclusions Gefitinib is effective and tolemble in the treatment of patients with advanced NSCLC failed to prior chemotherapy.
出处 《医学信息(内.外科版)》 2009年第8期680-681,684,共3页 Medical Information Operations Sciences Fascicule
关键词 非小细胞肺癌 吉非替尼 non - small cell lung cancer (NSCLC) gefitinib.
  • 相关文献

参考文献8

二级参考文献61

共引文献151

同被引文献9

  • 1Scagliotti GV,de-Marinis F, Rinaldi M,et aL Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer [ J ]. J Clin Oncol, 2002,20 ( 21 ) : 4285 - 4291. 被引量:1
  • 2Thatcher N, Chang A, Parikh P, et aL Gefitinib plus best support- ive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo controlled, multieentre study( Iressa Survival Evaluation in lung cancer) [ J ]. Lancet ,2005,366 ( 9496 ) : 1527 - 1537. 被引量:1
  • 3Shepherd FA, Percira JR, Ciulcanu T,et al. Erlotinib in previously treated non-small lung cancer [J]. N Engl J Med,2005,353 (2) :123 - 132. 被引量:1
  • 4Paez JG,Janne PA,Lee JC,et al. EGFR mutations in lung cancer : Correlation with clinical response to gefitinib therapy [ J ]. Science,2004,304(4) : 1497 - 1500. 被引量:1
  • 5Huang SF, Liu HP, Li H, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non- small cell lung cancers related to gefitinib responsiveness in Taiwan [ J ]. Clin Cancer Res,2004,10 ( 24 ) : 8195 - 8203. 被引量:1
  • 6Satouchi M, Negoro S, Funada Y,et al. Predictive factors associated with prolonged survival in patients with advanced non-smallcell lung cancer(NSCLC) treated with gefitinib[J]. Br J Cancer, 2007,96(8) :1191 - 1196. 被引量:1
  • 7Gatzemeier U,Pluzanska A,Szczesna A,et al. Phase Ⅲ study of erlotinib in combination with eisplatin and gemcitabine in advanced non-small-cell lung cancer:The tarceva lung cancer inves-tigation trial[J]. J Clin On col,2007,25 ( 12 ) : 1545 - 1552. 被引量:1
  • 8黄进肃,董强刚,许凯黎,韩宝惠,白皓,耿沁,周瑾.血清循环DNA的EGFR基因突变与肺癌选择性靶向治疗研究[J].肿瘤,2007,27(12):968-972. 被引量:8
  • 9刘哲峰,赵宏,焦顺昌.吉非替尼一线治疗晚期非小细胞肺癌临床分析[J].中国肿瘤临床,2009,36(5):249-252. 被引量:6

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部